Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Abstract

Treatment with novel agents during a clinical trial is indicated for patients with metastatic RCC after progression to cytokine treatment. Three prognostic factors for predicting survival were used to categorize patients into risk groups. These risk categories can be used in clinical trial design and interpretation.